Skip to main content
. 2022 Feb 21;9(4):ofac093. doi: 10.1093/ofid/ofac093

Figure 3.

Figure 3.

Percentages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein haplotypes in nasopharyngeal samples from Casirivimab-Imdevimab-treated patients on days 0, 3, and 7. The number of SARS-CoV-2 spike protein haplotypes (2, 3, or 4 haplotypes) increased over time post-monoclonal antibodies infusion.